Tecfidera (dimethyl fumarate)

10:22 EST 20th November 2017 | BioPortfolio

TECFIDERA® (dimethyl fumarate) is an oral therapy approved in the United States for the treatment of relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis (RRMS), which is the most common form of the disease. TECFIDERA has been proven to significantly reduce important measures of disease activity, including relapses and development of brain lesions, as well as to slow disability progression over time, while demonstrating a favorable safety and tolerability profile.

Quick Search

review and buy Tecfidera (dimethyl fumarate) market research data and corporate reports here